Albireo Pharma Inc IPO-Jahr
Was ist das IPO-Jahr von Albireo Pharma Inc?
IPO-Jahr von Albireo Pharma Inc ist 2016
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit ipo-jahr ähnlich Albireo Pharma Inc
- The Toronto-Dominion Bank PFD SER 9 3.7% hat IPO-Jahr von 2015
- Fura Gems hat IPO-Jahr von 2015
- Hostess Brands hat IPO-Jahr von 2015
- Nabriva Therapeutics Plc hat IPO-Jahr von 2015
- REF hat IPO-Jahr von 2015
- H-Source hat IPO-Jahr von 2015
- Albireo Pharma Inc hat IPO-Jahr von 2016
- American Pacific Borates hat IPO-Jahr von 2017
- Razer hat IPO-Jahr von 2017
- DEAG Deutsche Entertainment Aktiengesellschaft hat IPO-Jahr von 2017
- Hamilton Beach Brands Co hat IPO-Jahr von 2017
- Artelo Biosciences hat IPO-Jahr von 2017
- VARTA AG hat IPO-Jahr von 2017